Platelet phosphorylated TDP-43: an exploratory study for a peripheral surrogate biomarker development for Alzheimer's disease

AIM: Alzheimer's disease (AD) and other forms of dementia create a noncurable disease population in world's societies. To develop a blood-based biomarker is important so that the remedial or disease-altering therapeutic intervention for AD patients would be available at the early stage. MA...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilhite, Rodger, Sage, Jessica M, Bouzid, Abdurrahman, Primavera, Tyler, Agbas, Abdulbaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2017
Materias:
Preliminary Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674277/
https://www.ncbi.nlm.nih.gov/pubmed/29134122
http://dx.doi.org/10.4155/fsoa-2017-0090
Descripción
Sumario:AIM: Alzheimer's disease (AD) and other forms of dementia create a noncurable disease population in world's societies. To develop a blood-based biomarker is important so that the remedial or disease-altering therapeutic intervention for AD patients would be available at the early stage. MATERIALS & METHODS: TDP-43 levels were analyzed in postmortem brain tissue and platelets of AD and control subjects. RESULTS: We observed an increased TDP-43 (<60%) in postmortem AD brain regions and similar trends were also observed in patient's platelets. CONCLUSION: Platelet TDP-43 could be used as a surrogate biomarker that is measurable, reproducible and sensitive for screening the patients with some early clinical signs of AD and can be used to monitor disease prognosis.

Ejemplares similares